Papers/PMID:42504019
Efficacy of Empagliflozin on Liver Enzymes, Lipid Profile and BMI in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Systematic Review and Meta-Analysis.
Endocrinology, diabetes & metabolism2026The record
3 findings · 1 compound · 3 endpoints · 2 null
What it reported
How to read these marksWhat moved
1 finding
empagliflozin — decreases body mass index
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“The random‐effects analysis of four RCTs comprising 315 patients with MASLD showed that Empagliflozin significantly reduced BMI (WMD −0.71 kg/m2; 95% CI: −1.00 to −0.43, p < 0.001) and showed negligible heterogeneity (I 2 = 0%).”
Quoted verbatim from Efficacy of Empagliflozin on Liver Enzymes, Lipid Profile and BMI in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Systematic Review and Meta-Analysis.. - Study
- meta-analysis
- Dose
- 10 mg/day
- Population
- Adults with MASLD (previously NAFLD or NASH), with or without type 2 diabetes; four RCTs
Effect -0.71 mean difference, 95% CI -1 to -0.43
Efficacy of Empagliflozin on Liver Enzymes, Lipid Profile and BMI in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Systematic Review and Meta-Analysis.2026PMID:42504019Permalink
What did not
2 findings
empagliflozin — no detected effect on total cholesterol (TC)
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“Analysis of four RCTs including 335 patients suggested no significant effect of empagliflozin on TC (WMD = −8.07 mg/dL, 95% CI: −24.49 to 8.35, p = 0.335; I 2 = 83.5%).”
Quoted verbatim from Efficacy of Empagliflozin on Liver Enzymes, Lipid Profile and BMI in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Systematic Review and Meta-Analysis.. - Study
- meta-analysis
- Dose
- 10 mg/day
- Population
- Adults with MASLD (previously NAFLD or NASH), with or without type 2 diabetes; four RCTs
Effect -8.07 mean difference, 95% CI -24.49 to 8.35
Efficacy of Empagliflozin on Liver Enzymes, Lipid Profile and BMI in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Systematic Review and Meta-Analysis.2026PMID:42504019Permalink
empagliflozin — no detected effect on LDL cholesterol
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“The pooled data from five RCTs (377 participants) indicated that empagliflozin did not significantly alter LDL‐C levels (WMD = −8.45 mg/dL, 95% CI: −33.33 to 16.43, p = 0.329; I 2 = 88.5%).”
Quoted verbatim from Efficacy of Empagliflozin on Liver Enzymes, Lipid Profile and BMI in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Systematic Review and Meta-Analysis.. - Study
- meta-analysis
- Dose
- 10 mg/day
- Population
- Adults with MASLD (previously NAFLD or NASH), with or without type 2 diabetes; five RCTs
Effect -8.45 mean difference, 95% CI -33.33 to 16.43
Efficacy of Empagliflozin on Liver Enzymes, Lipid Profile and BMI in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Systematic Review and Meta-Analysis.2026PMID:42504019Permalink